“…Richard Pratley describes some of the important cardiovascular safety trials of novel therapeutic agents for diabetes, which suggest that certain approaches may convey specific cardiovascular outcome benefits . Finally, Robert Chilton and Mark Kearney, in two contributions, discuss an aspect of cardiovascular disease that has increasingly been seen as important in insulin‐resistant states: congestive heart failure. New understandings and treatments of congestive heart failure have emerged as analysis of the safety trials has proceeded.…”